When you’re diagnosed with breast cancer, one of the biggest questions is often: “What is the risk that my cancer could come back?” The answer is not always straightforward and two breast cancers that appear very similar based on size, stage, or even subtype can behave very differently over time. This is where genomic recurrence […]

For many patients diagnosed with hormone receptor-positive breast cancer, anastrozole is a cornerstone of treatment — and understanding its effects matters from day one. Anastrozole belongs to a class of drugs called aromatase inhibitors, which work by blocking the enzyme responsible for converting androgens into estrogen. Reducing estrogen levels helps slow or stop the growth […]

After a lumpectomy, one of the first questions on your mind is probably: when can I get back to work? There might be real pressure to return quickly, from employers, due to finances, or your own desire to reclaim normalcy. But the answer is rarely as simple as “one week,” and pushing too hard, too […]

A study published last week in the Journal of the National Cancer Institute reported on the results of the KARISMA trial. The trial results showed promise for (Z)-endoxifen, a tamoxifen metabolite, as an alternative to the popular tamoxifen treatment (but with fewer side effects) due to its ability to reduce breast density. A reduction in […]